The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 20, 2010

Filed:

Apr. 30, 2007
Applicants:

Gihad Dargazanli, Cachan, FR;

Genevieve Estenne-bouhtou, Chevilly-Larue, FR;

Florence Medaisko, Saint Maur des Fosses, FR;

Nathalie Rakotoarisoa, Longiumeau, FR;

Inventors:

Gihad Dargazanli, Cachan, FR;

Genevieve Estenne-Bouhtou, Chevilly-Larue, FR;

Florence Medaisko, Saint Maur des Fosses, FR;

Nathalie Rakotoarisoa, Longiumeau, FR;

Assignee:

sanofi-aventis, Paris, FR;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/55 (2006.01); A61K 31/4025 (2006.01); C07D 233/04 (2006.01); C07D 207/20 (2006.01);
U.S. Cl.
CPC ...
Abstract

Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine. Moreover, the compounds of the invention may be used for treating painful muscle contracture in rheumatology and in acute spinal pathology; for treating spastic contractures of medullary or cerebral origin; for the symptomatic treatment of acute and subacute pain of light to moderate intensity; for treating intense and/or chronic pain, neurogenic pain and intractable pain; for treating Parkinson's disease and Parkinson-like symptoms of neurodegenerative origin or induced by neuroleptics; for treating partial primary and secondary generalized epilepsy of simple or complex symptomology, mixed forms and other epileptic syndromes in addition to another antiepileptic treatment, or in monotherapy, for the treatment of sleep apnea, and for neuroprotection.


Find Patent Forward Citations

Loading…